bosentan

Known as: 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide, bosentán, 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide 
A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2018
05010015019942018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
BACKGROUND Treatments for pulmonary arterial hypertension have been mainly studied in patients with advanced disease (WHO… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVES Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
RATIONALE Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment. OBJECTIVES To… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
  • D Stolz, H Rasch, +4 authors M Tamm
  • The European respiratory journal
  • 2008
Pulmonary hypertension during exercise is common in severe chronic obstructive pulmonary disease (COPD). It was hypothesised that… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Eisenmenger syndrome is characterized by the development of pulmonary arterial hypertension with consequent… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
RATIONALE Small, open-label studies suggest that combinations of existing therapies may be effective for pulmonary arterial… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Primary pulmonary hypertension (PPH) is a progressive disease with high mortality. Administration of i.v. epoprostenol has… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE Recurrent digital ulcers are a manifestation of vascular disease in patients with systemic sclerosis (SSc; scleroderma… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a cause of pulmonary hypertension. We… (More)
Is this relevant?